U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H12N4O5
Molecular Weight 244.205
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIBAVIRIN

SMILES

C([C@]1([H])[C@]([H])([C@]([H])([C@]([H])(n2cnc(C(=O)N)n2)O1)O)O)O

InChI

InChIKey=IWUCXVSUMQZMFG-AFCXAGJDSA-N
InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1

HIDE SMILES / InChI

Molecular Formula C8H12N4O5
Molecular Weight 244.205
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adf16e64-345f-469a-b987-3fbdd17e0ac2 | http://www.news-medical.net/health/Ribavirin-History.aspx

Ribavirin is a synthetic nucleoside analogue, which was first discovered and developed in 1970 by researchers from the International Chemical & Nuclear Corporation (ICN), today known as Valeant Pharmaceuticals. Ribavirin was initially approved for use in humans to treat pediatric respiratory syncytial virus infections (RSV). In cell cultures the inhibitory activity of ribavirin for RSV is selective. The mechanism of action is unknown. Reversal of the in vitro antiviral activity by guanosine or xanthosine suggests ribavirin may act as an analogue of these cellular metabolites. There were no other significant advancements in the treatment of hepatitis C until 1998, when the combination of ribavirin and interferon-alpha gained approval. Clinically, ribavirin showed a small, additive antiviral effect in combination with interferon, but its main effect was dose-dependent prevention of virological relapse. The mechanism by which the combination of ribavirin and an interferon product exerts its effects against the hepatitis C virus has not been fully established. However, it could be thorough the inhibition of inosine monophosphate dehydrogenase (IMPDH), which is the key step in de novo guanine synthesis, a requirement for viral replication.

Originator

Curator's Comment:: Ribavirin was first discovered and developed in 1970 by researchers from the International Chemical & Nuclear Corporation (ICN), today known as Valeant Pharmaceuticals. Chemists Joseph T. Witkovski and Ronald K. Robins had a main role in synthesizing this compound.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VIRAZOLE

Approved Use

VIRAZOLE (Ribavirin for Inhalation Solution, USP) is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy. Only severe RSV lower respiratory tract infection should be treated with VIRAZOLE. The vast majority of infants and children with RSV infection have disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of VIRAZOLE aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with VIRAZOLE should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection. Use of aerosolized VIRAZOLE in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with this mode of administration and the specific ventilator being used

Launch Date

5.04835211E11
Primary
COPEGUS

Approved Use

COPEGUS in combination with PEGASYS (peginterferon alfa-2a) is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Launch Date

1.03887359E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3680 ng/mL
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIBAVIRIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
228000 ng × h/mL
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIBAVIRIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
298 h
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIBAVIRIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 21 years
n = 1
Health Status: unhealthy
Condition: respiratory syncytial virus (RSV) infection
Age Group: 21 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hyperuricemia, Injury to kidney...
AEs leading to
discontinuation/dose reduction:
Hyperuricemia (severe, 1 patient)
Injury to kidney (acute, 1 patient)
Sources:
2400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2400 mg, 1 times / day
Sources:
unhealthy, 39.9 years (range: 27 - 51 years)
n = 3
Health Status: unhealthy
Condition: generalized lymphadenopathy
Age Group: 39.9 years (range: 27 - 51 years)
Sex: M
Population Size: 3
Sources:
Disc. AE: Nausea, Vomiting...
Other AEs: CNS disorder (NOS), Fatigue...
AEs leading to
discontinuation/dose reduction:
Nausea (1 patient)
Vomiting (1 patient)
Headache (severe, 1 patient)
Hematocrit low (1 patient)
Other AEs:
CNS disorder (NOS) (severe, 3 patients)
Fatigue (3 patients)
Sources:
16 mg/kg 4 times / day multiple, intravenous
Highest studied dose
Dose: 16 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 16 mg/kg, 4 times / day
Sources:
unhealthy, 6-10 years
n = 2
Health Status: unhealthy
Condition: La Crosse viral encephalitis
Age Group: 6-10 years
Sex: F
Population Size: 2
Sources:
Disc. AE: Nonprotein nitrogen blood increased, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Nonprotein nitrogen blood increased (1 patient)
Abdominal pain (1 patient)
Tenderness (1 patient)
Anorexia (1 patient)
Pancreatic enzymes increased (1 patient)
Pancreatitis (1 patient)
Sources:
1200 mg 1 times / day multiple, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
pregnant
Other AEs: Fetal death...
1200 mg 1 times / day multiple, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: chronic hepatitis C virus infection
Sources:
AEs

AEs

AESignificanceDosePopulation
Injury to kidney acute, 1 patient
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 21 years
n = 1
Health Status: unhealthy
Condition: respiratory syncytial virus (RSV) infection
Age Group: 21 years
Sex: M
Population Size: 1
Sources:
Hyperuricemia severe, 1 patient
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 21 years
n = 1
Health Status: unhealthy
Condition: respiratory syncytial virus (RSV) infection
Age Group: 21 years
Sex: M
Population Size: 1
Sources:
Hematocrit low 1 patient
Disc. AE
2400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2400 mg, 1 times / day
Sources:
unhealthy, 39.9 years (range: 27 - 51 years)
n = 3
Health Status: unhealthy
Condition: generalized lymphadenopathy
Age Group: 39.9 years (range: 27 - 51 years)
Sex: M
Population Size: 3
Sources:
Nausea 1 patient
Disc. AE
2400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2400 mg, 1 times / day
Sources:
unhealthy, 39.9 years (range: 27 - 51 years)
n = 3
Health Status: unhealthy
Condition: generalized lymphadenopathy
Age Group: 39.9 years (range: 27 - 51 years)
Sex: M
Population Size: 3
Sources:
Vomiting 1 patient
Disc. AE
2400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2400 mg, 1 times / day
Sources:
unhealthy, 39.9 years (range: 27 - 51 years)
n = 3
Health Status: unhealthy
Condition: generalized lymphadenopathy
Age Group: 39.9 years (range: 27 - 51 years)
Sex: M
Population Size: 3
Sources:
Fatigue 3 patients
2400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2400 mg, 1 times / day
Sources:
unhealthy, 39.9 years (range: 27 - 51 years)
n = 3
Health Status: unhealthy
Condition: generalized lymphadenopathy
Age Group: 39.9 years (range: 27 - 51 years)
Sex: M
Population Size: 3
Sources:
Headache severe, 1 patient
Disc. AE
2400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2400 mg, 1 times / day
Sources:
unhealthy, 39.9 years (range: 27 - 51 years)
n = 3
Health Status: unhealthy
Condition: generalized lymphadenopathy
Age Group: 39.9 years (range: 27 - 51 years)
Sex: M
Population Size: 3
Sources:
CNS disorder (NOS) severe, 3 patients
2400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2400 mg, 1 times / day
Sources:
unhealthy, 39.9 years (range: 27 - 51 years)
n = 3
Health Status: unhealthy
Condition: generalized lymphadenopathy
Age Group: 39.9 years (range: 27 - 51 years)
Sex: M
Population Size: 3
Sources:
Abdominal pain 1 patient
Disc. AE
16 mg/kg 4 times / day multiple, intravenous
Highest studied dose
Dose: 16 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 16 mg/kg, 4 times / day
Sources:
unhealthy, 6-10 years
n = 2
Health Status: unhealthy
Condition: La Crosse viral encephalitis
Age Group: 6-10 years
Sex: F
Population Size: 2
Sources:
Anorexia 1 patient
Disc. AE
16 mg/kg 4 times / day multiple, intravenous
Highest studied dose
Dose: 16 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 16 mg/kg, 4 times / day
Sources:
unhealthy, 6-10 years
n = 2
Health Status: unhealthy
Condition: La Crosse viral encephalitis
Age Group: 6-10 years
Sex: F
Population Size: 2
Sources:
Nonprotein nitrogen blood increased 1 patient
Disc. AE
16 mg/kg 4 times / day multiple, intravenous
Highest studied dose
Dose: 16 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 16 mg/kg, 4 times / day
Sources:
unhealthy, 6-10 years
n = 2
Health Status: unhealthy
Condition: La Crosse viral encephalitis
Age Group: 6-10 years
Sex: F
Population Size: 2
Sources:
Pancreatic enzymes increased 1 patient
Disc. AE
16 mg/kg 4 times / day multiple, intravenous
Highest studied dose
Dose: 16 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 16 mg/kg, 4 times / day
Sources:
unhealthy, 6-10 years
n = 2
Health Status: unhealthy
Condition: La Crosse viral encephalitis
Age Group: 6-10 years
Sex: F
Population Size: 2
Sources:
Pancreatitis 1 patient
Disc. AE
16 mg/kg 4 times / day multiple, intravenous
Highest studied dose
Dose: 16 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 16 mg/kg, 4 times / day
Sources:
unhealthy, 6-10 years
n = 2
Health Status: unhealthy
Condition: La Crosse viral encephalitis
Age Group: 6-10 years
Sex: F
Population Size: 2
Sources:
Tenderness 1 patient
Disc. AE
16 mg/kg 4 times / day multiple, intravenous
Highest studied dose
Dose: 16 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 16 mg/kg, 4 times / day
Sources:
unhealthy, 6-10 years
n = 2
Health Status: unhealthy
Condition: La Crosse viral encephalitis
Age Group: 6-10 years
Sex: F
Population Size: 2
Sources:
Fetal death grade 5
1200 mg 1 times / day multiple, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
pregnant
Overview

OverviewOther

Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Synthesis of tetrazole ribonucleosides and their evaluation as antiviral agents.
1976 Feb
Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus.
1976 Mar
Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
1992 Aug 21
Selective inhibition of arthropod-borne and arenaviruses in vitro by 3'-fluoro-3'-deoxyadenosine.
1992 Jun
(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
1992 Jun 12
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
1992 Nov 27
[ROC curve analysis of factors predictive of response to treatment with interferon plus ribavirin in patients with chronic hepatitis C relapse after previous interferon treatment].
2002 Dec
[Novel mode of action of ribavirin (Rebetol), a drug for the treatment of chronic hepatitis C: inducting the mutation of RNA viruses].
2002 Dec
Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.
2002 Jul
Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C.
2002 Jul
Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrole.
2002 Jul 23
Interferon-alpha induced transient thyroid dysfunction in hepatitis C.
2002 Mar
Inhibition of the replication of a hepatitis C virus-like RNA template by interferon and 3'-deoxycytidine.
2002 Nov
Inhibitors of the IMPDH enzyme as potential anti-bovine viral diarrhoea virus agents.
2002 Nov
The quest for an efficacious antiviral for respiratory syncytial virus.
2002 Nov
Search of antimicrobial activity of selected non-antibiotic drugs.
2002 Nov-Dec
Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds.
2002 Oct
Treatment of acute hepatitis C virus infection with interferon-alpha 2b and ribavirin: case report and review of the literature.
2002 Oct 14
U.S. veterans' experience with rebetron in a nonstudy environment: success or failure?
2002 Sep
Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.
2002 Sep
Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.
2002 Sep
Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C.
2002 Sep-Oct
Anemia in the treatment of hepatitis C virus infection.
2003
Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.
2003
Hemoglobinuria with ribavirin treatment.
2003 Apr
Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats.
2003 Apr 15
Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency.
2003 Aug
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma.
2003 Aug
Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon.
2003 Aug 15
[Is chronic hepatitis C treatment as efficient in the general population as in randomised trials?].
2003 Aug-Sep
Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
2003 Feb
Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin.
2003 Feb
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
2003 Feb
In vitro activity of potential anti-poxvirus agents.
2003 Jan
Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.
2003 Jan
Successful treatment of giant cell hepatitis with Rebetron (interferon/ribavirin).
2003 Jan
Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication.
2003 Jul
[52-year-old patient with subcutaneous space-occupying lesion in immunosuppression].
2003 Jun
Correlation of sICAM-1 and sVCAM-1 level with biochemical, histological and viral findings in chronic hepatitis C after interferon-alpha + ribavirin therapy.
2003 Jun
Severe migraine headaches are caused by ribavirin but not by interferon alpha-2B in combination therapy for chronic hepatitis C.
2003 Jun
Ribavirin and alpha interferon enhance death receptor-mediated apoptosis and caspase activation in human hepatoma cells.
2003 Jun
A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C.
2003 Jun
The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.
2003 Jun 5
Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses.
2003 Mar
Two distinct phases of virus-induced nuclear factor kappa B regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells.
2003 May 16
How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration?
2003 Nov
[Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C].
2003 Oct
Rosacea fulminans associated with pegylated interferon alpha-2B and ribavirin therapy.
2003 Oct
Intracerebral haemorrhage and hepatitis C treatment.
2003 Sep
Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV.
2003 Sep-Oct
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adf16e64-345f-469a-b987-3fbdd17e0ac2
respiratory syncytial virus infection: 20 mg/mL VIRAZOLE (Ribavirin for inhalation solution) as the starting solution in the drug reservoir of the SPAG-2 unit, with continuous aerosol administration for 12-18 hours per day for 3 to 7 days. Using the recommended drug concentration of 20 mg/mL the average aerosol concentration for a 12 hour delivery period would be 190 micrograms/liter of air. Aerosolized VIRAZOLE should not be administered in a mixture for combined aerosolization or simultaneously with other aerosolized medications. Chronic hepatitis C virus infection: The recommended duration of treatment for patients previously untreated with ribavirin and interferon is 24 to 48 weeks. The daily dose of COPEGUS (ribavirin) tablets is 800 mg to 1200 mg administered orally in two divided doses. The dose should be individualized to the patient depending on baseline disease characteristics (eg, genotype), response to therapy, and tolerability of the regimen.
Route of Administration: Other
To determine the optimal concentration and timing of ribavirin treatment for the inhibition of viral transcription, Human A549 pulmonary type II epithelial cells pretreated (2 h) or posttreated (1 h) with increasing concentrations of ribavirin (from10 to 100 microg/ml) were exposed to pRSV (Respiratory syncytial virus). Total cellular RNA was harvested 36 h later, and the abundance of the 1.1-kb RSV N transcript was measured by Northern blotting. Ribavirin treatment potently inhibited RSV transcription, thereby reducing the level of RSV N transcripts to approximately 13% of levels in nontreated cells. In RSV-infected epithelial cells, ribavirin reduces plaque formation, the release of infectious virions, and F glycoprotein expression.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:54:48 UTC 2021
Edited
by admin
on Fri Jun 25 20:54:48 UTC 2021
Record UNII
49717AWG6K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIBAVIRIN
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
COPEGUS
Brand Name English
COTRONAK
Brand Name English
RIBAVIRIN [USP MONOGRAPH]
Common Name English
RBV
Common Name English
RIBAVIRIN [INN]
Common Name English
1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE, 1-.BETA.-D-RIBOFURANOSYL-
Common Name English
RIBAVIRIN [HSDB]
Common Name English
RIBAVIRIN [EMA EPAR]
Common Name English
SCH 18908
Code English
SCH-18908
Code English
NSC-163039
Code English
RIBAVIRIN BIOPARTNERS
Brand Name English
RIBAVIRIN [MI]
Common Name English
RIBAVIRIN TEVA PHARMA B.V.
Brand Name English
REBETOL
Brand Name English
RIBAVIRIN MYLAN
Brand Name English
RIBAVIRIN [EP MONOGRAPH]
Common Name English
RIBAVIRIN [VANDF]
Common Name English
RIBAVIRIN [JAN]
Common Name English
RIBAVIRIN [MART.]
Common Name English
RIBAVIRIN [ORANGE BOOK]
Common Name English
RIBAVIRIN COMPONENT OF PEGINTERFERON
Common Name English
VIRAZOLE
Brand Name English
RIBASPHERE
Brand Name English
RIBAVIRIN [WHO-DD]
Common Name English
RIBAVIRIN [USAN]
Common Name English
RIBAVIRIN TEVA
Brand Name English
1-.BETA.-D-RIBOFURANOSYL-1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE
Common Name English
RIBAVIRIN [USP-RS]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175466
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
EMA ASSESSMENT REPORTS RIBAVIRIN TEVA (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
WHO-ATC J05AP01
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
FDA ORPHAN DRUG 57491
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
EMA ASSESSMENT REPORTS RIBAVIRIN TEVA PHARMA B.V. (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
LIVERTOX 842
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
WHO-VATC QJ05AB04
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
EMA ASSESSMENT REPORTS COTRONAK (REFUSED: HEPATITIS C, CHRONIC)
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
EU-Orphan Drug EU/3/01/024
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.3
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
NCI_THESAURUS C281
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
EMA ASSESSMENT REPORTS REBETOL (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
WHO-ATC J05AB04
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
EMA ASSESSMENT REPORTS RIBAVIRIN BIOPARTNERS (WITHDRAWN: HEPATITIS C, CHRONIC)
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
FDA ORPHAN DRUG 162402
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
EMA ASSESSMENT REPORTS RIBAVIRIN MYLAN (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C807
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
INN
3543
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
ChEMBL
CHEMBL1643
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
MESH
D012254
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
CAS
36791-04-5
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
EVMPD
SUB10297MIG
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
USP_CATALOG
1602706
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY USP-RS
JAPANESE REVIEW
COPEGUS
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY APPROVED MARCH 2015
LACTMED
Ribavirin
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
MERCK INDEX
M9593
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY Merck Index
EPA CompTox
36791-04-5
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
DRUG BANK
DB00811
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
HSDB
6513
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
IUPHAR
6842
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
CAS
66510-90-5
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
SUPERSEDED
RXCUI
9344
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
RIBAVIRIN
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
FDA UNII
49717AWG6K
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
DRUG CENTRAL
2373
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
PUBCHEM
37542
Created by admin on Fri Jun 25 20:54:48 UTC 2021 , Edited by admin on Fri Jun 25 20:54:48 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
TARGET ORGANISM->INHIBITOR
A guanine derivative approved for treating HCV and respiratory syncytial virus (RSV) that has been evaluated in patients with SARS and MERS, but its side effects such as anaemia may be severe at high doses.
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite; Excreted renally
METABOLITE -> PARENT
BY adenosine kinase
METABOLITE -> PARENT
a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite; excreted renally.
PRODRUG -> METABOLITE ACTIVE
METABOLITE -> PARENT
by the successive action of nucleoside mono- and di-phosphate kinases
MAJOR
PLASMA
Related Record Type Details
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 2.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
ACTIVE MOIETY